HTFL insider buying and SEC filings, explained
Heartflow, Inc. · CIK 1464521
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$1.1M
Insiders who bought
1
Sold (not marked 10b5-1)
$115.0M
Planned sales (10b5-1)
$26.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 22, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 23,933 shares at $55.01 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 25% to 73,453 shares. | SEC filing Filed Oct 26, 2026, 6:00 PM ET |
| Oct 12, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 38,900 shares at about $49.57 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 12% to 283,014 shares. | SEC filing Filed Oct 14, 2026, 6:05 PM ET |
| Sep 18, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 19,682 shares at $50.15 ($987K), marked as a 10b5-1 plan trade. Holdings down 20% to 79,956 shares. | SEC filing Filed Sep 21, 2026 |
| Sep 17–18, 2026 | Planned (10b5-1) | Vikram Verghese (CFO) sold 24,345 shares between Sep 17 and Sep 18 at about $50.55 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 14% to 155,183 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 11–15, 2026 | Planned (10b5-1) | Vikram Verghese (CFO) sold 34,975 shares between Sep 11 and Sep 15 at about $50.08 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 16% to 179,528 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 10–11, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 38,900 shares between Sep 10 and Sep 11 at about $46.78 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 11% to 321,914 shares. | SEC filing Filed Sep 14, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Vikram Verghese (CFO) sold 6,640 shares at about $50.03 ($332K), marked as a 10b5-1 plan trade. Holdings down 3% to 214,503 shares. | SEC filing Filed Sep 10, 2026 |
| Sep 2–3, 2026 | Planned (10b5-1) | Vikram Verghese (CFO) sold 33,416 shares between Sep 2 and Sep 3 at about $49.85 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 13% to 221,143 shares. | SEC filing Filed Sep 4, 2026 |
| Aug 21, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 27,230 shares at $50.00 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 7% to 360,814 shares. | SEC filing Filed Aug 25, 2026 |
| Aug 18, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 32,676 shares at $45.00 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 8% to 388,044 shares. | SEC filing Filed Aug 20, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 9,219 shares at $41.23 ($380K), marked as a 10b5-1 plan trade. Holdings down 10% to 86,459 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 14, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 15,560 shares at $39.06 ($608K), marked as a 10b5-1 plan trade. Holdings down 4% to 420,720 shares. | SEC filing Filed Aug 18, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 22,562 shares at $28.31 ($639K), marked as a 10b5-1 plan trade. Holdings down 5% to 436,280 shares. | SEC filing Filed Aug 12, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 9,219 shares at $25.72 ($237K), marked as a 10b5-1 plan trade. Holdings down 9% to 88,731 shares. | SEC filing Filed Jul 17, 2026 |
| Jul 10, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 22,562 shares at $27.75 ($626K), marked as a 10b5-1 plan trade. Holdings down 5% to 435,373 shares. | SEC filing Filed Jul 13, 2026 |
| Jun 24, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 38,900 shares at $35.00 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 8% to 457,935 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 22,562 shares at $28.50 ($643K), marked as a 10b5-1 plan trade. Holdings down 4% to 496,835 shares. | SEC filing Filed Jun 12, 2026 |
| May 18, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 9,219 shares at $28.34 ($261K), marked as a 10b5-1 plan trade. Holdings down 10% to 78,731 shares. | SEC filing Filed May 20, 2026 |
| May 11, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 22,562 shares at $29.12 ($657K), marked as a 10b5-1 plan trade. Holdings down 4% to 519,397 shares. | SEC filing Filed May 13, 2026 |
| Apr 28–30, 2026 | Sale | Bain Capital Life Sciences Investors, LLC (10% owner) sold 2,000,000 shares indirectly between Apr 28 and Apr 30 at about $29.45 ($58.9M). Indirect holdings down 19% to 8,448,158 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Apr 30, 2026 |
| Apr 10, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 22,562 shares at $26.72 ($603K), marked as a 10b5-1 plan trade. Holdings down 4% to 549,163 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 64,533 shares at about $24.64 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 44% to 81,002 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 19, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 64,533 shares at about $25.69 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 45% to 78,518 shares. | SEC filing Filed Mar 23, 2026 |
| Mar 18, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 9,725 shares at $25.00 ($243K), marked as a 10b5-1 plan trade. Holdings down 2% to 571,725 shares. | SEC filing Filed Mar 20, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 12,837 shares at $22.66 ($291K), marked as a 10b5-1 plan trade. Holdings down 2% to 581,450 shares. | SEC filing Filed Mar 12, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Julie A Cullivan (Director) sold 9,122 shares at $25.00 ($228K), marked as a 10b5-1 plan trade. Holdings down 25% to 27,291 shares. | SEC filing Filed Mar 6, 2026 |
| Feb 12, 2026 | Planned (10b5-1) | Campbell Rogers (Chief Medical Officer) sold 65,153 shares at about $24.49 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 46% to 76,034 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 10, 2026 | Planned (10b5-1) | John C.M. Farquhar (CEO and Director) sold 22,562 shares at about $27.46 ($620K), marked as a 10b5-1 plan trade. Holdings down 4% to 591,656 shares. | SEC filing Filed Feb 10, 2026 |
| Feb 5, 2026 | Planned (10b5-1) | Julie A Cullivan (Director) sold 8,000 shares at $27.32 ($219K), marked as a 10b5-1 plan trade. Holdings down 18% to 36,413 shares. | SEC filing Filed Feb 6, 2026 |
| Feb 4, 2026 | Sale | Bain Capital Life Sciences Investors, LLC (10% owner) sold 2,000,000 shares indirectly at $28.05 ($56.1M). Indirect holdings down 16% to 10,448,158 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Feb 6, 2026 |
| Dec 16, 2025 | Purchase (code P) | Jeffrey C Lightcap (Director) bought 40,000 shares at about $26.34 ($1.1M), reported as a purchase (code P). New position of 40,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow HTFL in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.